OBJECTIVE: Macrophages influence their environment and surrounding immune cells as soon as stimulators affect them. Different sources of macrophages induce different reactions in their neighboring immune cells,which result in non-uniform immunologic outcomes. In this experimental research, we compare the behavior of peritoneal macrophages to lipopolysaccharide (LPS) stimulation from BALB/cmice as an indicator of a type 2 immune response and from C57BL/6 mice as an indicator of a type 1 immune response. MATERIALS AND METHODS: In this experimental study, peritoneal macrophages prepared from thioglycolate stimulated BALB/c and C57BL/6 micewere treated with 1µg/ml LPS. At different time points after LPS treatment, nitric oxide (NO), interferon gamma (IFN-λ), interleukin 4 (IL-4),transforming growth factor β1(TGF-β1), interleukin 17 (IL-17), and interleukin 10(IL-10) production were measured in the supernatants of all macrophage cultures. Indoleamine 2, 3 dioxygenase (IDO) and phagocytic activitywere analyzed in the different experimental groups. The supernatant effects of LPS-treated macrophages on splenocyte proliferation was assessed by the colorimetric method using a 3-(4,5-Dimethylthiazol- 2-yl)-2, 5-diphenyltetrazolium bromide (MTT) reagent. RESULTS: According to cytokine analysis, different mouse strains show different cytokine patterns in response to LPS. C57BL/6 macrophages produced more IL-17, IL-10, and IFN-λ, while BALB/c macrophages produced more TGF-β1 and IL-4. There was no significant difference in IDO activity between strains (p≤0.05). BALB/c mice produced more NO inthe first 24 hours after LPS treatment,but C57BL/6 produced more NO at 72 hours post-LPS treatment. Macrophages from both strains hada suppressor effect on splenocyte proliferation, but this effect was stronger in BALB/c mice. CONCLUSION: The results show that macrophages from different genetic backgrounds respond differently to the same stimulus in aspects of type, intensity, and time of response. The consideration of these aspects will enableresearchers to use correct treatment programs for immune-regulation or immunotherapy.
OBJECTIVE: Macrophages influence their environment and surrounding immune cells as soon as stimulators affect them. Different sources of macrophages induce different reactions in their neighboring immune cells,which result in non-uniform immunologic outcomes. In this experimental research, we compare the behavior of peritoneal macrophages to lipopolysaccharide (LPS) stimulation from BALB/cmice as an indicator of a type 2 immune response and from C57BL/6 mice as an indicator of a type 1 immune response. MATERIALS AND METHODS: In this experimental study, peritoneal macrophages prepared from thioglycolate stimulated BALB/c and C57BL/6 micewere treated with 1µg/ml LPS. At different time points after LPS treatment, nitric oxide (NO), interferon gamma (IFN-λ), interleukin 4 (IL-4),transforming growth factor β1(TGF-β1), interleukin 17 (IL-17), and interleukin 10(IL-10) production were measured in the supernatants of all macrophage cultures. Indoleamine 2, 3 dioxygenase (IDO) and phagocytic activitywere analyzed in the different experimental groups. The supernatant effects of LPS-treated macrophages on splenocyte proliferation was assessed by the colorimetric method using a 3-(4,5-Dimethylthiazol- 2-yl)-2, 5-diphenyltetrazolium bromide (MTT) reagent. RESULTS: According to cytokine analysis, different mouse strains show different cytokine patterns in response to LPS. C57BL/6 macrophages produced more IL-17, IL-10, and IFN-λ, while BALB/c macrophages produced more TGF-β1 and IL-4. There was no significant difference in IDO activity between strains (p≤0.05). BALB/c mice produced more NO inthe first 24 hours after LPS treatment,but C57BL/6 produced more NO at 72 hours post-LPS treatment. Macrophages from both strains hada suppressor effect on splenocyte proliferation, but this effect was stronger in BALB/c mice. CONCLUSION: The results show that macrophages from different genetic backgrounds respond differently to the same stimulus in aspects of type, intensity, and time of response. The consideration of these aspects will enableresearchers to use correct treatment programs for immune-regulation or immunotherapy.
Macrophages are major responders of innate immunity
by expression of innate immunity receptors
and their ability to sense host and pathogenderived
factors (1, 2). Macrophages are phagocytic
cells that act both as a host for immune evasion of intra-cellular pathogens and as promoters to
prime a specific immune response by antigen presentation
and secretion of pro-inflammatory cytokines
and chemokines (3). Experimental studies
show that the early immune responses appearing
after a pathogenic challenge determine the polarization
of T cell responses and disease outcome.
Different early immune responses mediated with
the help of macrophages assist with induction of
cellular immunity andthe control of immune homeostasis
(4). In every immune stimulation or infection,
a heterogeneous population of macrophages
will activate and produce pro-inflammatory to
anti-inflammatory responses, depending on the
nature of the stimulators and the induced signaling
pathways. Evidence shows that macrophages from
Th1 strains (C57BL/6) or Th2 strains (BALB/c) of
mice are activated in different ways in response
to the same stimuli,guiding the immune responses
in opposing directions (4, 5). According to this
functional diversity, macrophages can be divided
into distinct groups, M-1 and M-2 that influence
the formation of Th1/Th2 and other inflammatory
responses (4, 5). Because of the variety in macrophage
function of different strains, and the key
role of macrophages in infections and inflammatory
disease, targeted studies should be designed
to clarify the role of macrophages under different
conditions. The obtained results will create a helpful
map for better manipulation of macrophages by
using suitable treatments or stimuli.Much of the current knowledge on the function
of macrophages in response to immunomodulatorshas
been derived from the analysis of the RAW
264.7 cell line. This cell linehas been established
from the ascites of tumor-induced BALB/c mice
(6, 7). However these results are not extendable tothose
macrophages that havebeen separated from
distinct anatomical parts of the body,and therefore
have different characteristics. Splenic, alveolar, or
peritoneal macrophages are examples of distinct
anatomic macrophage sources (8, 9). Researchers
have shown that large peritoneal macrophages
(LPMs) and small peritoneal macrophages (SPMs)
are two developmentally and functionally distinct
macrophage subsets that respond differently to typical
stimuli, such as lipopolysaccharides (LPS) (9).
LPSis a pathogen-specific molecular motif that,
after interaction with toll-like receptor-4 (TLR-4)
on macrophages, induces macrophage migration
to the infected site through actin reassembly (10).
Following genetic reprogramming in activated
macrophages the expression of TLR-4 mediated
signaling genes isup-regulated that terminated to
the activation ofnuclear factor κB (NFκB),mitogen
activated protein kinases (MAP kinases), and finally
the expression of pro-inflammatory cytokine
genes (1, 6, 11).The goal of our study was to compare peritoneal
macrophage responsesto LPS stimulation from
two different genetic backgrounds over a determined
period of time.Thioglycolate stimulation
was used to induce inflammation and migration
of blood monocytes to the peritoneal fluid (9). At
different times after LPS treatment,we measured
phagocytic activity, cytokine pattern, IDO activity,
and nitric oxide (NO) production of the macrophages.
Materials and Methods
Mice
Six, eight-week-oldfemale BALB/c and C57BL/6
mice were purchased from Pasteur Institute of Iran.
Mice wereused for splenocyte and peritoneal macrophage
preparation. All animal experiments followed
the guidelines of the Laboratory Animal
Ethical Commission of Tarbiat Modares University.
Macrophage preparation
Peritoneal macrophages from BALB/c and
C57BL/6 mice were obtainedby the peritoneal
lavage technique.Four days after peritoneal injection
of 4% w/v thioglycolate medium (2 ml), mice
were ethically sacrificed by CO2 inhalation.A total
of 8 ml of cold RPMI-1640, supplemented with
1% penicillin-streptomycin (Gibco, Grand Island,
NY, USA)was injected into the peritoneal cavityin
the lower abdominal area near the fat region. After
needle withdrawal, mice were held by theirtails
and swishedaround to wash the peritoneal cavity.
The needle was inserted into the upper part of the
abdomen and peritoneal fluids were collected.
The resultant cell suspension was centrifuged at
350×g for 5 minutes and adjusted to1×106 cells/
ml in RPMI-1640 (Sigma-Aldrich, St. Louis,
MO, USA) that contained 10% fetal bovine serum
(FBS), 2 mM of 1% L-glutamine, 10 mM of 1%
HEPES, and 1% penicillin-streptomycin (Gibco,
Grand Island, NY, USA). Aliquots of each sample
(200 µl) were cultured in 4-well plates and incubated at 37˚C and 5% CO2. After 6 hours, the
cells were washed to separate out any nonadhesive
cells.Macrophage purity was determined by
flow-cytometry analysis for CD14+ and CD11b+
markers.
Lipopolysaccharide (LPS) treatment
For in vitro stimulation,we added LPS to a final
concentration of 1 µg/ml to the macrophage
cultures. This step was performedin triplicate.
We assessed immunological parameters of themacrophage
culture supernatants at 0 (just prior
to LPS addition), and 3, 24, 48, and 72 hourspost-
LPS treatment. The immunomodulatory
effect of the immune responses on splenocytes
was measured by culturing thesplenocytes in
the supernatant of LPS-treated macrophages.
The lack of LPS in the reagents and cell culture
media wasconfirmed by the limulus amebocyte
lysate (LAL) test.
Cytokine measurement
Supernatants of the LPS-stimulated macrophages
were collected at 0 (pre-treatment),and
3, 24, 48, and 72 hours post-LPS treatment.
Supernatants from different experiments were
stored at -20˚C. The presence of interferon
gamma (IFN-λ), interleukin 4 (IL-4), transforming
growth factor β1 (TGF-β1), interleukin
17 (IL-17), and interleukin 10 (IL-10) cytokines
were assessed using enzyme-linked immunosorbent
assay (ELISA) kits from eBioscience,
following the manufacturer’s instructions.Each
sample was dispensed in triplicate. The optical
density of each well was determined at 450
nm. We used Microsoft Excel to draw standard
curves and ELISA results.
Indoleamine 2, 3 dioxygenase (IDO) activity assay
Indoleamine 2, 3 dioxygenase (IDO) activity
was determined bythe colorimetric assay that
measured the amount of kynurenine, the first
stable catabolite downstream of the enzyme’s
activity. Briefly, 100 µl of 30% trichloroacetic
acid was added to 200 µl culture supernatants of
the control and test groups. After centrifugation
at 8000×g, 75 µl of the supernatant from each
sample was added to an equal volume of Ehrlich
reagent (100 mg P-dimethylbenzaldehyde, 5 mL
glacial acetic acid) in microliter 96-well plates,
in triplicate. Optical density was measured at 492
nm. We calculated the amount of kynurenine according
to the standard curve of defined kynurenine
concentration (0-100 µM).
Nitric oxide (NO) measurement
All supernatants from LPS-treated macrophages
were collected and stored at-20˚C. (This has already
been mentioned. One should be deleted.) Nitrite
was measured by addition of 100µl of Griess
reagent (1% sulphanilamide and 0.1% naphthylenediamine
in 5% phosphoric acid; Sigma) to 100
µl of the supernatants. Optical density was read at
540 nm and NO concentration was determined by
using the standard concentrations of sodium nitrite
(0-100 µM).
Splenocyte proliferation assay
BALB/c×C57BL/6 hybrid mice (4) spleens were
removed and homogenized in 2 ml cell culture media.
After centrifugation, erythrocytes were lysed
bylysis buffer that consisted of NH4Cl (0.15 M),
KHCO3 (1.0 mM), and Na2EDTA (0.1 mM). The
splenocytes were washed three times in media
and cultured in RPMI-1640 (Sigma-Aldrich, St.
Louis, MO, USA) that contained 5% FBS, 1% Lglutamine
(2 mM), 1% HEPES (10 mM), and 1%
penicillin-streptomycin (Gibco, Grand Island, NY,
USA). Splenocytes were counted and adjusted to
5×105 cells/ml. A total of 50µl of the cell suspension
was co-cultured with 150 µl of the 0 (pretreatment),
and 3, 24, 48, and 72 hour LPS-treated
macrophage supernatants. Each sample was
tested in triplicate. After incubation for 7 hours at
37˚C and 5%CO2, 10 µl 3- (4, 5-Dimethylthiazol-
2-yl)-2, 5-diphenyltetrazolium bromide (MTT;
Sigma-Aldrich, St. Louis, MO, USA) was added
to each well and the plates were incubated for an
additional 6 hours (12). Formazan crystals were
dissolved in 200 µl of dimethyl sulfoxide (DMSO;
Sigma-Aldrich, St. Louis, MO, USA). Optical
density was read at 540 nm on the plate reader usinga
reference wavelength of 630 nm. Cell count
was determined according to standard curve.
Phagocytosis assay
Peritoneal macrophages from BALB/c and
C57BL/6 mice were seeded at a concentration of
10×104) cells/well in a 4-well plate. After 0 (pretreatment),
and 3, 24, 48, and 72 hours of LPS treatment, cells were washed and 4', 6-diamidino-
2-phenylindole (DAPI)-stained Saccharomyces
cerevisiae were added at a ratio of 5:1 cells to each
well. Cells were incubated for 1hour at 37˚C and
5% CO2 , then washed carefully to remove all yeast
particles. Control and test samples were examined
under an inverted fluorescence microscope. At
least 200 cells were counted and the percent of
infected cells and phagocytic index was reported.
Statistical analysis
Data analysis was performed with SPSS Statistical
Package (SPSS Inc., Chicago, IL, USA)
version 11.0. Differences between means were assessed
for statistical differences using Mann-Whitney
non-parametric assays and one-way analysis
of variance (ANOVA). P<0.05 was statistically
significant. The results are shown asmean ± standard
deviation (SD).
Results
Flowcytometry
We used various samples of prepared peritoneal
macrophages from BALB/c and C57BL/6
mice for the flowcytometry measurement of
macrophage specific cellsurface markers, CD14
and CD11b. As indicated in figure 1, the mean
percentage of CD14 positive cells was 93.95 ±
4, and the mean percentage of CD11b positive
cells was 97.6 ± 1.15.
Cytokine assay
To determine the nature of the immune responses
of macrophages from BALB/c and
C57BL/6 mice to LPS stimulation, we measured
the amount of IFN-λ, IL-4, TGF-β1, IL-17, and
IL-10 produced in the supernatant at 0 (pre-LPS
treatment), and 3, 24, 48, and 72 hours post-
LPS treatment. As shown in figure 2, TGF-β1
production increased significantly (p≤0.05) in
BALB/c macrophages compared to C57BL/6
macrophages in response to LPS. Cytokine
analysis showed that IL-17 production was
induced in both mice groups after LPS stimulation,
but the production level of C57BL/6
macrophages was significantly higher than the
production level of BALB/c macrophages at 0
(pre-stimulation), and 3, 24, and 48 hours poststimulation.
A significant increase in IL-17 production
occurred at 3 hours post-LPS treatment
in C57BL/6 macrophages, but it occurredlater
in BALB/c macrophages (48 hours). According
to figure 2, IL-10 production was induced in both
groups of mice; however, it was significantly higher
in C57BL/6 macrophages compared to BALB/c
macrophages at 3 and 48 hours post-stimulation. A
significant increase in IL-10 production occurred
at 3 hours post-LPS treatment in C57BL/6 macrophages;
however, this occurred later in BALB/c
macrophages (24 hours). A small increase (about
2 pg) in IL-4 production was detected after LPS
stimulation,which was significantly higher in
BALB/c macrophages compared to C57BL/6 macrophages
at 72 hours post-treatment. IFN-λ production
increased significantly in C57BL/6 macrophages
compared to BALB/c macrophages at 3, 24, 48
and 72 hours post-LPS treatment.Flow cytometry analysis of peritoneal macrophages
for CD11b and CD14 markers. Data shows the average number
of positive cellsforfivemice per experimental group ± standard
deviation.TGF-β1, IL-17, IL-10, 1L-4, and IFN-λ production by LPS-stimulated BALB/c and C57BL/6 macrophages at 0 (pretreatment),
and 3, 24, 48, and 72 hours post-LPS treatment. The results represent the mean cytokine levels (pg/ml) forfive mice
per experimentalgroup in triplicate ± tandard deviation. The single star on top of the bars shows the significant difference
between BALB/c and C57BL/6 groups.
Measurement of indoleamine 2, 3 dioxygenase
activity
IDO activity was assessed by kynurenine
measurement in the supernatant of LPS-stimulated
macrophages. According to figure 3, IDO
activity increased in both mice groups after LPS
treatment, but this increase was not statisticallysignificant.
There was no difference between
BALB/c and C57BL/6 macrophages in kynurenine
production.
Nitric oxide measurement
NO production was measured in the supernatant
of BALB/c and C57BL/6 macrophages
at different time points after LPS treatment.
NO production increased significantly in both
groups after LPS stimulation (Fig 4). The increasing
pattern of NO production at different
time points differed betweenBALB/c and
C57BL/6 macrophages. At 3 and 24 hours after
LPS stimulation, BALB/c macrophages produced
significantly higher amounts of NO than
C57BL/6 macrophages. However,at 72 hours
after LPS stimulation C57BL/6 macrophages
produced significantly higher amounts of NO
than BALB/c macrophages.
Fig 4
Nitric oxide (NO) production by BALB/c and
C57BL/6 peritoneal macrophages at 0 (pre-treatment), and
3, 24, 48 and 72 hours post-LPS treatment. Data shows the
mean NO level (µM) for five mice per experimental group in
triplicate ± standard deviation. The single star on top of the
bars showsthe significant difference between BALB/c and
C57BL/6 groups.
Kynurenine production by BALB/c and C57BL/6
peritoneal macrophages at 0 (pre-treatment), and 3, 24, 48,
and 72 hours post-LPS treatment. Data shows the mean
kynurenine level (µM) for five mice per experimentalgroup
in triplicate ± standard deviation.Nitric oxide (NO) production by BALB/c and
C57BL/6 peritoneal macrophages at 0 (pre-treatment), and
3, 24, 48 and 72 hours post-LPS treatment. Data shows the
mean NO level (µM) for five mice per experimental group in
triplicate ± standard deviation. The single star on top of the
bars showsthe significant difference between BALB/c and
C57BL/6 groups.
Macrophage supernatant effect on splenocyte
proliferation
An MTT assay was used to determine the effects
of the supernatant from LPS-treated BALB/c and
C57BL/6 macrophages on splenocyte proliferation.
According to the stimulation index in Fig5,
proliferation of splenocytes was inhibited in the
presence of the supernatant from LPS-treated
macrophages. Stimulation index decreased significantly
in the presence of the supernatants of
72-hour LPS-treated macrophages from BALB/c
and C57BL/6 mice. There was no significant difference
between the inhibitory effect of the supernatants
of BALB/c and C57BL/6 macrophages.Lymphoproliferative responses of F1 hybrid mice
(BALB/c x C57BL/6) spleen cells to the supernatants of
BALB/c and C57BL/6 peritoneal macrophages at 0 (pretreatment),
and 3, 24, 48, and 72 hours post-LPS treatment.
The results represent the average of SI for five mice per ex
perimental group in triplicate ± standard deviation.LPS-treated peritoneal macrophages from
BALB/c, and C57BL/6 mice were incubated for
1hour with DAPI stained Saccharomyces cerevisiae
at a 5: 1 ratio. After the incubation period,we analyzed
the cells under a fluorescence microscope (Fig
6). In the different microscopic fields that were analyzed,
we counted the number of cells that had internalized
Saccharomyces cerevisiae and the number of
internalized Saccharomyces cerevisiaeper cell. The
mean numbers of cells that contained Saccharomyces
cerevisiae per total cell were reported as percent of
phagocytosis (Fig 7A). The number of Saccharomyces
cerevisiae ingested per phagocytewas reported as
the phagocytic index (Fig 7B). There was significant
phagocytosis in both mice groups after 24 hours of
LPS treatment. In addition, longer incubation with
medium that containedLPS had a positive effect on
phagocytosis. There was no significant difference between
the percent of phagocytosis between BALB/c
and C57BL/6 mice. According to the phagocytic index
(Fig 7B), LPS treatment had a stimulatory effect
on the number of internalized Saccharomyces cerevisiae.
There was a significant difference between
BALB/c and C57BL/6 mice according to the phagocytic
index. As shown in figure 7, the mean number
of internalized Saccharomyces cerevisiae after 72
hours of LPS treatment in C57BL/6 macrophages
(9.7) was significantly higher than observed with
BALB/c macrophages (3.6).
Fig 6
Phagocytosis of DAPI-stained Saccharomyces cerevisiae
by C57BL/6 and BALB/c macrophages at 72 hours
post-LPS treatment. A, B represent phase contrast and C, D
represent florescent microscopy images of the macrophages
after incubation for one hour with Saccharomyces cerevisiae
(×400).
Fig 7
The mean numbers of macrophages that contain Saccharomyces cerevisiae per total macrophages at 0 (pre-treatment),
and 3, 24, 48 and 72 hours post-LPS treatment (7 A). The meannumber of Saccharomyces cerevisiae ingested per phagocyte
at 0 (pre-treatment), and 3, 24, 48, and 72 hours post-LPS treatment (7 B). The single star on top of the bars shows significant
difference between BALB/c and C57BL/6 groups.
Phagocytosis of DAPI-stained Saccharomyces cerevisiae
by C57BL/6 and BALB/c macrophages at 72 hours
post-LPS treatment. A, B represent phase contrast and C, D
represent florescent microscopy images of the macrophages
after incubation for one hour with Saccharomyces cerevisiae
(×400).The mean numbers of macrophages that contain Saccharomyces cerevisiae per total macrophages at 0 (pre-treatment),
and 3, 24, 48 and 72 hours post-LPS treatment (7 A). The meannumber of Saccharomyces cerevisiae ingested per phagocyte
at 0 (pre-treatment), and 3, 24, 48, and 72 hours post-LPS treatment (7 B). The single star on top of the bars shows significant
difference between BALB/c and C57BL/6 groups.
Discussion
Numerous studies of macrophage function have
shownvarious stimulators such macrophage responses
to specific stimulatorssuch as LPS. These
studies encompass the effects of LPS on genetic
reprogramming and the expression of pro-inflammatory
genes (11, 13), the signal transduction of
LPS/TLR4 (6, 14, 15), inhibitors and stimulators
of LPS function (7, 16-20), and macrophage migratory
and inflammatory response to LPS (10,
21). In spite of that, all studies have done with the
same cells called macrophages, and the same stimulus
called LPS; we see discrepancies in results
that make it difficult to use the same stimulus like
LPS in a correct way for obtaining the favorite result.
According to aliterature review, variationsin
macrophage preparation and genetic background
explain these discrepancies.Ghosn et al. (9) have shown that the peritoneal
cavity contains two different macrophage subsets,
LPMs and SPMs that differ developmentally,
physically, and functionally. They demonstrated
that after thioglycolate stimulation, a population
of blood monocytes infiltrate into the peritoneal
cavity and mature as SPMs. SPMs express CD62L
(L-selectin) and can migrate to other lymphoid
organs as antigen presenting cells (APCs). Previous
studies have shown that macrophages can be
divided functionally to M-1/M-2 (5) according to
their cytokine pattern and their effective role in the
induction of Th1/Th2 in surrounding lymphocytes.
In the current study, we have compared the effects
of LPS on the function of thioglycolate-stimulated
peritoneal macrophages in BALB/c and C57BL/6
mice as representatives of the Th2 and Th1 immune
response, respectively. After separation of the peritoneal
macrophages, their purity was confirmed by
flowcytometry measurement of the CD11b marker.
Our results showed thatthioglycolate stimulation
induced CD14 expression in 93% of peritoneal
macrophages. Fock et al. (21) demonstrated that
only about 58% of peritoneal macrophages expressed
CD14 without stimulation. Macrophages
responded to LPS in the presence of CD14 and
the TLR-4/MD-2 receptor complex.This result has
shown that pre-separation thioglycolate stimulation
may prepare macrophages to respond better
to the next in vitro LPS stimulation.There was no
difference between CD14 expression in BALB/c
and C57BL/6 macrophages. A time course study
of macrophage cytokine production after 1 µg/
ml LPS treatment showed that LPS could induce
cytokine production of thioglycolate-stimulated
macrophages. There were more TGF-β1 cytokines
(1500 pg/ml) produced by BALB/c macrophages
compared to those produced by C57BL/6
macrophages (400 pg/ml) at 72 hours post-LPS
treatment.A larger quantity of IFN-λ cytokines (130
pg/ml) were produced by C57BL/6 macrophages
compared to the quantity of IFN-λ cytokines (30
pg/ml) produced by BALB/c macrophages at 72
hours post-LPS treatment. These results confirmed
the dominant M-2/M-1 responses of BALB/c and
C57BL/6 macrophages. Our results indicated that
during the first hours after LPS treatment the quantity of IL-17 and IL-10 produced by C57BL/6
macrophages was significantly higher than
BALB/c macrophages; after 72 hours of LPS
treatment both macrophages produced the same
quantity of IL-17 and IL-10 cytokines. This result
was the first comparative report on IL-17 and
IL-10 production by LPS-stimulated peritoneal
macrophages. The results have suggested that the
different pattern of IL-17 and IL-10 cytokine production
at the first 72 hours after LPS treatment
in C57BL/6 and BALB/c macrophages were determinant
in the formation of the M-1/M-2 microenvironment
and induction of Th1/Th2 immune
responses. As indicated in figure 3, IL-4 production
by BALB/c macrophages wassignificantly
higher than C57BL/6 macrophages at 72 hours
after LPS treatment. The results demonstrated
that during thefirst hours after LPS treatment,
BALB/c macrophages produced more nitrite than
C57BL/6 macrophages. After 72 hours, C57BL/6
macrophages produced significantly more nitrite
compared to BALB/c macrophages. This result
contrasted the previous reported results on the
inhibitory effect of TGF-β1 production on iNOS
activity and nitrite production (22, 23). This contrast
has explained the bi-directional modulatory
effect of TGF-β1 on macrophages. TGF-β1
induces pro-inflammatory responses in resting
macrophages, but induces anti-inflammatory responses
in active macrophages according to their
cytokine milieu (24).In addition, the higher amount of nitrite production
at 3 and 24 hours post-LPS treatment in
BALB/c macrophages contrasted previous M2
macrophage behavior after LPS treatment. This
could be explained by previous reports, which have
shown that macrophages differentially metabolize
arginine through arginase or iNOS activation, depending
on the inflammatory condition (4, 25, 26).
This contrast is related to different inflammatory
conditions surrounding the BALB/c macrophagesin
the first 24 hours in our experiment, which was
induced by thioglycolate stimulation (9).Previous studies have shown that activation of
IDO in macrophages hasan inhibitory effect on
T-cell proliferation (27). Some stimulators, like
macrophage colony-stimulating factor or a combination
of CD40 ligand and IFN-λ signals (28),
can induce IDO activity. Our results have shown
that both BALB/c and C57BL/6 macrophages
have IDO activity, with no difference between
the amounts of kynurenine produced between
them. In addition, LPS stimulation has no significant
effect on IDO activity. In order to study the
thioglycolate-stimulated macrophage effect on
splenocyte proliferation, splenocytes of F1 hybrid
BALB/c×C57BL/6 mice were cultured in the presence
of LPS-stimulated macrophage supernatants.
To eliminate the splenocyte response to foreign
antigens in the supernatant of macrophage cultures
and employing the same source of splenocyte,
F1 BALB/c×C57BL/6 mice were used for
splenocyte preparation (4). The results showed
that macrophage supernatants significantly inhibited
splenocyte proliferation at 72 hours post-LPS
treatment. This result agreed with the increase in
IDO activity at 72 hours post-LPS treatment in
both BALB/c and C57BL/6 mice, and increased
IL-10 and TGF-β1 production in C57BL/6 and
BALB/c mice, respectively.Phagocytosis is a complex
process in macrophages, whichare dependent
on both internal and environmental characteristics.
A phagocytosis assay can reflect the power of the
pathogen to resist elimination and the ability of
different macrophages and different macrophage
stimulators to combat these pathogens (3, 16, 29).
In this study, we have useda phagocytosis assay
to compare different genetic background effects
on phagocytosis. According to figure 7, we determined
that LPS stimulated phagocytosis in both
BALB/c and C57BL/6 macrophages. Data has
shown no significant difference in the number of
cells that phagocyte Saccharomyces cerevisiae,
but C57BL/6 macrophages have greater phagocytic
capacity. This result indicates that macrophages
with different genetic backgrounds will respond
to the same stimuli with different kinetics and in a
different capacity. Variations in quality and quantity
of phagocytic capacity, cytokine, and NO production
at different times after the encounter to the
same stimulus can explain the reason for different
immune outcomes between BALB/c and C57BL/6
mice in response to infections.
Conclusion
This comparative study shows that BALB/c and
C57BL/6 macrophages show different immune response
to LPS stimulation according to their Th2/
Th1 potential. Some discrepancies exist between BALB/c and C57BL/6 macrophages in terms of
their Th2 and Th1 behavior in immunologic response
to LPS. These discrepancies show that
LPScan modulate immune responses in different
ways, not only depending on genetic background,
but also on the current inflammatory
context of the immune system induced bythioglycolate
stimulation.This study represents the time course of immune
response events of macrophages to LPS
stimulation.The results enable us to select the
best time for additional analyses in futureexperiments.
Authors: Eva Monsalve; Almudena Ruiz-García; Victoriano Baladrón; María José Ruiz-Hidalgo; Beatriz Sánchez-Solana; Samuel Rivero; José J García-Ramírez; Antonio Rubio; Jorge Laborda; María José M Díaz-Guerra Journal: Eur J Immunol Date: 2009-09 Impact factor: 5.532
Authors: Zhili Yao; Jessica M Mates; Alana M Cheplowitz; Lindsay P Hammer; Andrei Maiseyeu; Gary S Phillips; Mark D Wewers; Murugesan V S Rajaram; John M Robinson; Clark L Anderson; Latha P Ganesan Journal: J Immunol Date: 2016-08-17 Impact factor: 5.422
Authors: Souptik Basu; Indra N Choudhury; Jia Yu Peppermint Lee; Anu Chacko; Jenny A K Ekberg; James A St John Journal: Cells Date: 2022-08-04 Impact factor: 7.666
Authors: Stefan Schülke; Lothar Vogel; Ann-Christine Junker; Kay-Martin Hanschmann; Adam Flaczyk; Stefan Vieths; Stephan Scheurer Journal: J Immunol Res Date: 2016-06-01 Impact factor: 4.818
Authors: Julia Rex; Ute Albrecht; Christian Ehlting; Maria Thomas; Ulrich M Zanger; Oliver Sawodny; Dieter Häussinger; Michael Ederer; Ronny Feuer; Johannes G Bode Journal: PLoS Comput Biol Date: 2016-07-27 Impact factor: 4.475